- Home
- SST vs AEON Comparison
SST vs AEON Comparison
Compare SST & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | AEON |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 300 | 5 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 26.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SST | AEON |
|---|---|---|
| Price | $1.77 | $1.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $7.20 |
| AVG Volume (30 Days) | 19.3K | ★ 71.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.38 |
| 52 Week High | $11.30 | $1.45 |
Technical Indicators
Market Signals| Indicator | SST | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 16.84 | 52.83 |
| Support Level | $0.34 | $0.69 |
| Resistance Level | $4.61 | $1.42 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 5.88 | 62.99 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.